Baby formula company stops production again due to storms

It is unclear when the facility will restart production

Related video: Mother confronts woman over hoarding baby formula amid shortage crisis

Leer en Español

Abbott Nutrition, a Michigan baby formula factory whose temporary shuttering contributed to the formula shortage, has once again closed, this time due to inclement weather.

MLive reports that the factory suspended production on its EleCare specialty formulas, but noted that there is enough supply to meet current demand.

The company ramped up production of the formula for infants with severe food allergies and digestive problems prior to the second shut down.

The factory was damaged and needs re-sanitizing following severe thunderstorms and heavy rains that moved through Michigan on Monday. The company did not specify the extent of the damage to the facility.

“Severe thunderstorms and heavy rains came through southwestern Michigan on Monday evening, resulting in high winds, hail, power outages and flood damage throughout the area,” Abbott said in a statement Wednesday night. “These torrential storms produced significant rainfall in a short period of time – overwhelming the city’s stormwater system in Sturgis, Mich., and resulting in flooding in parts of the city, including areas of our plant."

US Food and Drug Administration Commissioner Dr Robert Califf said in a tweet that the agency would be working alongside Abbott to get the facility back up and producing as soon as possible.

“We know Abbott is working quickly to assess the damage and will be reporting its progress to us in the days ahead. Once the company establishes a plan, FDA will be back in the facility working to ensure that they can restart producing safe and quality formula products quickly,” he wrote.

Abbott restarted production at the factory on 4 June after contamination issues forced it to close back in February, which ultimately was a major factor in the formula shortage plaguing the nation.

In February, the Food and Drug Administration launched an investigation into four bacterial infections that affected infants who consumed the factory's powdered formulas. Two of those babies died, which resulted in the closure.

The company has insisted that its products were not directly related to the infections.

FDA inspectors ultimately found numerous violations at the plant, including bacterial contamination, leaks in the roof, and insufficient safety protocols.

Following the inquiry, Abbot recalled several of its leading brands, including Similac.

The company has not said when its facility would re-open.

“As a result, Abbott has stopped production of its EleCare specialty formula that was underway to assess damage caused by the storm and clean and re-sanitize the plant," the company said. "We have informed FDA and will conduct comprehensive testing in conjunction with the independent third party to ensure the plant is safe to resume production. This will likely delay production and distribution of new product for a few weeks.”

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in